申请人:HOFFMANN LA ROCHE
公开号:WO2017060202A1
公开(公告)日:2017-04-13
The present invention relates to compounds of formula I; wherein R1' is CH3 R1 is methyl, ethyl, CF3, CH2OH, cyclopropyl or cyano, or R1 and R1 may form together a l,l-dioxo-tetrahydro-thiophen-3-yl ring; R is hydrogen, methyl, ethyl, isopropyl, tert-butyl, cyclopropyl, hydroxmethyl, or 2-propyl- 2-ol; RJ is CI, F, CF3, cyano, methyl, methoxy, isopropyl, or cyclopropyl; R4 is hydrogen, methyl, F or CI; or to a pharmaceutically acceptable salt or acid addition salt, to a racemic mixture, or to its corresponding enantiomer and/or optical isomer and/or stereoisomer thereof. The compounds of formula I may be used in the treatment of psychiatric disorders such as schizophrenia, bipolar disorder, obsessive-compulsive disorder or autism spectrum disorder. It has been surprisingly been found that the compounds of general formula I are EAAT3 inhibitors. The excitatory amino acid transporter 3 (EAAT3), also referred to in human studies as solute carrier family 1, member 1 (systematic gene name: SLC1A1) and in rodents as excitatory amino acid carrier 1 (EAAC1), is a high-affinity anionic amino acid transporter found in neurons throughout the cortex and in the hippocampus, basal ganglia (striatum, thalamus), and the olfactory bulb. EAAT3 functions to buffer local glutamate concentrations at excitatory synapses,
本发明涉及化合物的结构式I;其中R1'是CH3,R1是甲基、乙基、CF3、CH2OH、环丙基或氰基,或者R1和R1可以一起形成l,l-二氧-四氢噻吩-3-基环;R是氢、甲基、乙基、异丙基、叔丁基、环丙基、羟甲基或2-丙基-2-醇;RJ是CI、F、CF3、氰基、甲基、甲氧基、异丙基或环丙基;R4是氢、甲基、F或CI;或者是药用可接受的盐或酸加盐,或是外消旋混合物,或是对应的对映体和/或光学异构体和/或立体异构体。结构式I的化合物可用于治疗精神障碍,如精神分裂症、躁郁症、强迫症或自闭症谱系障碍。令人惊讶地发现,通用结构式I的化合物是EAAT3抑制剂。兴奋性氨基酸转运体3(EAAT3),在人类研究中也被称为溶质载体家族1,成员1(系统基因名:SLC1A1),在啮齿动物中被称为兴奋性氨基酸载体1(EAAC1),是一种在大脑皮层和海马体、基底神经节(纹状体、丘脑)和嗅球中发现的高亲和力阴离子氨基酸转运体。EAAT3的功能是缓冲兴奋突触处的局部谷氨酸浓度。